{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-141365","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.469620+00:00","generated_at":"2026-06-15T05:25:06.922850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Veru Q2 net loss $38.8M ($0.48/share); revenue falls to $6.6M; FDA agrees on sabizabulin Phase 3 design","bullets":["Net loss $38.8M vs $14.2M YoY; operating loss $39.4M including $3.9M impairment and $3.9M credit loss provision.","Revenue down to $6.6M from $13.0M; gross profit $4.1M vs $11.2M; R&D expense rose to $22.9M.","Cash and equivalents $23.5M at March 31, 2023, down from $80.2M at September 30, 2022.","FDA agreed on confirmatory Phase 3 trial for sabizabulin in COVID-19 ARDS; 408-subject, two interim efficacy analyses planned.","Sold ENTADFI for $20M plus up to $80M milestones; Lincoln Park Capital committed up to $100M common stock purchase."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-141365","json":"https://secwatch.observer/filing/0001193125-23-141365.json","markdown":"https://secwatch.observer/filing/0001193125-23-141365.md","text":"https://secwatch.observer/filing/0001193125-23-141365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312523141365/0001193125-23-141365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312523141365/d466660d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:25:06.922850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc8c02a575fe707fcd394437093f804e84d4e122","claim":"VERU INC. reported financial results for the quarter and six months ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Veru Inc. issued a press release (the \"Press Release\") announcing results for the quarter and six months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312523141365/0001193125-23-141365-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and six months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}